Dr. Gregory A. Prince
Science & Technology
Dr. Gregory A. Prince (1948-)
Gregory A. Prince was born and raised in Los Angeles, Calif. He attended Dixie College from 1965-67, graduating as valedictorian. He attended the UCLA School of Dentistry from 1969-73, again graduating as valedictorian. He received his Ph.D. in Pathology from UCLA in 1975, studying respiratory syncytial virus (RSV), the primary cause of infant pneumonia worldwide.
Over a period of 15 years at the National Institutes of Health and Johns Hopkins University, he and his co-workers developed the thesis that RSV disease could be prevented by administering antiviral antibodies to high-risk infants. He co-founded Virion Systems, Inc., to commercialize the thesis, and serves as its President and CEO. In 1989, Virion Systems and MedImmune, Inc., formed a joint venture to conduct clinical trials that ultimately resulted in the licensure by the Food and Drug Administration of RespiGam™ (1996), and Synagis ™ (1998) for the prevention of RSV pneumonia in high-risk infants. Synagis ™ is the first monoclonal antibody ever licensed for use against any infectious agent and its first-year sales made it one of the most successful biotech product launches in history.
In addition to a career in science, Dr. Prince has developed an avocation as a historian. His first book, Power From on High, The Development of Mormon Priesthood, was published in 1995, and he is currently writing a biography of LDS Church President David O. McKay. He and his wife, JaLynn Rasmussen Prince, are the parents of three children.